-
Je něco špatně v tomto záznamu ?
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission
A. Nagler, M. Labopin, B. Dholaria, D. Blaise, S. Bondarenko, J. Vydra, G. Choi, M. Rovira, P. Reményi, E. Meijer, CE. Bulabois, JL. Diez-Martin, I. Yakoub-Agha, E. Brissot, A. Spyridonidis, J. Sanz, A. Patel, M. Arat, A. Bazarbachi, G. Bug, BN....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
PubMed
36949658
DOI
10.1111/bjh.18765
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie * komplikace MeSH
- cyklofosfamid terapeutické užití MeSH
- lidé MeSH
- lokální recidiva nádoru etiologie MeSH
- nemoc štěpu proti hostiteli * MeSH
- nepříbuzný dárce MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Pre-transplant measurable residual disease (MRD) predicts relapse and outcome of allogeneic haematopoietic cell transplantation (allo-HCT). The impact of MRD on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT from a matched unrelated donor (UD) is unknown. This study assessed the impact of MRD in acute myeloid leukaemia (AML) in the first complete remission (CR1). A total of 272 patients (MRD negative [MRD-], n = 165; MRD positive [MRD+], n = 107) with a median follow-up of 19 (range: 16-24) months were studied. The incidence of grades II-IV and grades III-IV acute GVHD at day 180 was 25.2% and 25% (p = 0.99), and 10.6% and 6.8% (p = 0.29), respectively, and 2-year chronic GVHD was 35% and 30.4% (p = 0.96) in MRD+ and MRD- cohorts, respectively. In multivariate analysis, MRD+ status was associated with a higher incidence of relapse (RI) (hazard ratio [HR] = 2.56, 95% CI: 1.39-4.72), lower leukaemia-free survival (LFS) (HR = 2.04, 95% CI: 1.23-3.39), overall survival (OS) (HR = 1.83, 95% CI: 1.04-3.25) and GVHD-free, relapse-free survival (GRFS) (HR = 1.69, 95% CI: 1.10-2.58). MRD status did not have a significant impact on non-relapse mortality (NRM), or acute or chronic GVHD risk. Among patients with AML undergoing UD allo-HCT with PTCy, pre-transplant MRD+ status predicted a higher relapse rate, lower LFS, OS and GRFS.
Bone Marrow Transplantation Unit and Institute of Cell Therapy University of Patras Patras Greece
CHU de Lille Univ Lille INSERM U1286 Infinite Lille France
Department of Hematology Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Department of Hematology Institut Paoli Calmettes Marseille France
Department of Medicine 2 Hematology and Oncology Goethe University Frankfurt Frankfurt Germany
Division of Hematology Sheba Medical Center Tel Hashomer Israel
Haematology and BMT Ospedale San Raffaele s r l Milan Italy
Hematology Hôpital Saint Antoine Service d'Hématologie et Thérapie Cellulaire Paris France
Hematology Hospital Clinic Institute of Hematology and Oncology Barcelona Spain
Royal University Hospital Liverpool UK
Service d'Hématologie CHU Grenoble Alpes 38043 Grenoble France
Servicio de Hematología Institute of Hematology and Blood Transfusion Prague Czech Republic
Sisli Florence Nightingale Hospital Istanbul Turkey
Vanderbilt University Medical Center Nashville Tennessee USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011249
- 003
- CZ-PrNML
- 005
- 20240528143331.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.18765 $2 doi
- 035 __
- $a (PubMed)36949658
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Nagler, Arnon $u Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel $1 https://orcid.org/0000000207631265
- 245 10
- $a Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission / $c A. Nagler, M. Labopin, B. Dholaria, D. Blaise, S. Bondarenko, J. Vydra, G. Choi, M. Rovira, P. Reményi, E. Meijer, CE. Bulabois, JL. Diez-Martin, I. Yakoub-Agha, E. Brissot, A. Spyridonidis, J. Sanz, A. Patel, M. Arat, A. Bazarbachi, G. Bug, BN. Savani, S. Giebel, F. Ciceri, M. Mohty
- 520 9_
- $a Pre-transplant measurable residual disease (MRD) predicts relapse and outcome of allogeneic haematopoietic cell transplantation (allo-HCT). The impact of MRD on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT from a matched unrelated donor (UD) is unknown. This study assessed the impact of MRD in acute myeloid leukaemia (AML) in the first complete remission (CR1). A total of 272 patients (MRD negative [MRD-], n = 165; MRD positive [MRD+], n = 107) with a median follow-up of 19 (range: 16-24) months were studied. The incidence of grades II-IV and grades III-IV acute GVHD at day 180 was 25.2% and 25% (p = 0.99), and 10.6% and 6.8% (p = 0.29), respectively, and 2-year chronic GVHD was 35% and 30.4% (p = 0.96) in MRD+ and MRD- cohorts, respectively. In multivariate analysis, MRD+ status was associated with a higher incidence of relapse (RI) (hazard ratio [HR] = 2.56, 95% CI: 1.39-4.72), lower leukaemia-free survival (LFS) (HR = 2.04, 95% CI: 1.23-3.39), overall survival (OS) (HR = 1.83, 95% CI: 1.04-3.25) and GVHD-free, relapse-free survival (GRFS) (HR = 1.69, 95% CI: 1.10-2.58). MRD status did not have a significant impact on non-relapse mortality (NRM), or acute or chronic GVHD risk. Among patients with AML undergoing UD allo-HCT with PTCy, pre-transplant MRD+ status predicted a higher relapse rate, lower LFS, OS and GRFS.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nepříbuzný dárce $7 D061349
- 650 _2
- $a lokální recidiva nádoru $x etiologie $7 D009364
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 12
- $a akutní myeloidní leukemie $x komplikace $7 D015470
- 650 12
- $a nemoc štěpu proti hostiteli $7 D006086
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Labopin, Myriam $u INSERM UMRs 938, Sevice d'hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne University, Paris, France
- 700 1_
- $a Dholaria, Bhagirathbhai $u Vanderbilt University Medical Center, Nashville, Tennessee, USA $1 https://orcid.org/0000000323713655
- 700 1_
- $a Blaise, Didier $u Department of Hematology, Institut Paoli Calmettes, Marseille, France
- 700 1_
- $a Bondarenko, Sergey $u Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, First State Pavlov Medical University of St Petersburg, St Petersburg, Russian Federation
- 700 1_
- $a Vydra, Jan $u Servicio de Hematología, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Choi, Goda $u Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Rovira, Montserrat $u Hematology, Hospital Clinic, Institute of Hematology & Oncology, Barcelona, Spain
- 700 1_
- $a Reményi, Péter $u Haematology and Stem Cell Transplant, Dél-pesti Centrumkórház-Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary
- 700 1_
- $a Meijer, Ellen $u Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Bulabois, Claude Eric $u Service d'Hématologie, CHU Grenoble Alpes 38043, Grenoble, France
- 700 1_
- $a Diez-Martin, J L $u Department of Hematology, Hospital GU Gregorio Marañon, Instituto de Investigacion sanitaria Gregorio Marañon, Medicina, UCM, Madrid, Spain
- 700 1_
- $a Yakoub-Agha, Ibrahim $u CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
- 700 1_
- $a Brissot, Eolia $u Hematology, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France $1 https://orcid.org/000000034471418X
- 700 1_
- $a Spyridonidis, Alexandros $u Bone Marrow Transplantation Unit and Institute of Cell Therapy, University of Patras, Patras, Greece $1 https://orcid.org/0000000330972532
- 700 1_
- $a Sanz, Jaime $u Hematology Department at University Hospital La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
- 700 1_
- $a Patel, Amit $u Royal University Hospital, Liverpool, UK
- 700 1_
- $a Arat, Mutlu $u Sisli Florence Nightingale Hospital, Istanbul, Turkey
- 700 1_
- $a Bazarbachi, Ali $u Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
- 700 1_
- $a Bug, Gesine $u Department of Medicine 2, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany
- 700 1_
- $a Savani, Bipin N. $u Vanderbilt University Medical Center, Nashville, Tennessee, USA $7 xx0317726
- 700 1_
- $a Giebel, Sebastian $u Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch Wybrzeze Armii Krajowej, Gliwice, Poland
- 700 1_
- $a Ciceri, Fabio $u Haematology and BMT, Ospedale San Raffaele s.r.l, Milan, Italy $1 https://orcid.org/0000000308730123
- 700 1_
- $a Mohty, Mohamad $u INSERM UMRs 938, Sevice d'hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Sorbonne University, Paris, France $1 https://orcid.org/0000000185367781 $7 xx0317729
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 201, č. 6 (2023), s. 1169-1178
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36949658 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20240528143328 $b ABA008
- 999 __
- $a ok $b bmc $g 1963571 $s 1197514
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 201 $c 6 $d 1169-1178 $e 20230322 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20230718
